 Fortress Biotech, Inc. Common Stock: Nasdaq: FBIO Preferred Stock: Nasdaq: FBIOP Fortress, an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed and development-stage drugs and drug candidates, today announced that the underwriters of its recent public offering of its 9.375 Series A Cumulative Redeemable Perpetual Preferred Stock have exercised in full their option and purchased an additional 93,750 shares at the public offering price of 20.00 per share. 